OptiNose, Inc. (NASDAQ:OPTN) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Ramy Mahmoud - President and COO Vic Clavelli - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Gary Nachman - BMO Capital Markets Stacy Ku - Cowen Operator Good day, and thank you for standing by. Welcome to the OptiNose's Second Quarter 2022 Earnings Call. [Operator Instructions] Please be advised that today's conference is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

Building a Leading ENT / Allergy Specialty Company Corporate Presentation May 12, 2022 This presentation and our accompanying remarks contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: potential for continued XHANCE prescription and net revenue growth and factors supporting such ...

OptiNose, Inc. (NASDAQ:OPTN) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Keith Goldan - CFO Vic Clavelli - Chief Commercial Officer Ramy Mahmoud - President and COO Conference Call Participants Stacey Ku - Cowen Dave Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose First Quarter 2022 Earnings Conference Call. At thi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

OptiNose, Inc. (NASDAQ:OPTN) Q4 2021 Earnings Conference Call March 8, 2022 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations & Business Operations Peter Miller - Chief Executive Officer Ramy Mahmoud - President & Chief Operating Officer Victor Clavelli - Chief Commercial Officer Keith Goldan - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Dave Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Operator Good day, and thank ...

Building a Leading ENT / Allergy Specialty Company Corporate Presentation March 8, 2022 This presentation and our accompanying remarks contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: potential for continued XHANCE prescription and net revenue growth and factors supporting such ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from ___________ to ______________. Commission file number: 001-38241 FORM 10-K OPTINOSE, INC. ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact name of registrant as specified in its charter) For the fiscal year ended December 31, 2021 Delaware 42-1771610 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (I.R.S. Employer Id ...

OptiNose, Inc. (NASDAQ:OPTN) Q3 2021 Earnings Conference Call November 16, 2021 8:30 AM ET Company Participants Jonathan Neely - VP, IR & Business Operations Peter Miller - CEO & Director Keith Goldan - CFO Ramy Mahmoud - President & COO Conference Call Participants Gary Nachman - BMO Capital Markets David Amsellem - Piper Sandler David Steinberg - Jefferies Ken Cacciatore – Cowen Ladies and gentlemen, thank you for standing by, and welcome to the OptiNose Q3 2021 Earnings Call. At this time, all participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (S ...